Last updated on February 2019

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Brief description of study

An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia

Detailed Study Description

This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201.

No statistical hypothesis tests will be performed.

Clinical Study Identifier: NCT02970929

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.